Novartis, Roche blockbusters shine at ASCO

While experimental therapies grab a major chunk of the attention at the annual ASCO meeting, existing drugs have their share of new data to crow about. Here's a roundup of the biggest news coming out of the American Society of Clinical Oncology confab in Chicago. (For more on those experimental meds, see our sister pub, FierceBiotech).

  • The Novartis cancer pill Gleevec, already a major blockbuster approved to treat several forms of the disease, cleared a big hurdle in a gastrointestinal trial. The drug actually extended the lives of patients with a difficult-to-treat type of disease--GIST, or gastrointestinal stromal tumors--when used for three years after surgery, compared with the usual one-year regimen. It's the kind of data that's likely to change treatment protocols immediately, researchers said. Story | Report

  • Roche's Avastin cut the risk of ovarian cancer progression by 52 percent when added to chemotherapy, with median progression-free survival at 12.4 months for the Avastin patients and 8.4 months for the chemo-only group. In another study, the drug appeared to help newly diagnosed patients live longer--with 178 deaths in the Avastin group compared with 200 in the standard-therapy group--but it was in women with more advanced cancers that the drug worked most reliably to reduce the risk of death. Article

  • Johnson & Johnson's prostate cancer drug Zytiga improved patient survival time slightly better than in previous research, boosting it to 4.6 months from 3.9 months. Zytiga patients were found to live for a median of 15.8 months, compared with 11.2 months for placebo patients. The results came in a study that may have broader applications as well: Researchers found that patients who had the lowest levels of tumor cells circulating in their blood were more likely to survive than men who had more of them. Report | News

  • An estrogen-blocking drug that's now available as a generic helped reduce the risk of breast cancer by 65 percent in older women at high risk of developing the disease. Aromasin, a Pfizer drug, also had fewer side effects than commonly used preventives such as tamoxifen. News | Story

  • And last but not least, Eli Lilly's Alimta drug delayed progression of lung cancer by 1.3 months when used as a maintenance therapy in patients who were already treated with it as part of their first-round cancer cocktail. Lilly says it will use the data to support an FDA application for a new indication in maintenance therapy. Report | Article

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.